CA3168001A1 - Glp-1r and gcgr agonists, formulations, and methods of use - Google Patents
Glp-1r and gcgr agonists, formulations, and methods of use Download PDFInfo
- Publication number
- CA3168001A1 CA3168001A1 CA3168001A CA3168001A CA3168001A1 CA 3168001 A1 CA3168001 A1 CA 3168001A1 CA 3168001 A CA3168001 A CA 3168001A CA 3168001 A CA3168001 A CA 3168001A CA 3168001 A1 CA3168001 A1 CA 3168001A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- pharmaceutical dosage
- optionally
- administration
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980093P | 2020-02-21 | 2020-02-21 | |
| US62/980,093 | 2020-02-21 | ||
| US202063122108P | 2020-12-07 | 2020-12-07 | |
| US63/122,108 | 2020-12-07 | ||
| US202163133540P | 2021-01-04 | 2021-01-04 | |
| US63/133,540 | 2021-01-04 | ||
| PCT/US2021/018947 WO2021168386A1 (en) | 2020-02-21 | 2021-02-21 | Glp-1r and gcgr agonists, formulations, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3168001A1 true CA3168001A1 (en) | 2021-08-26 |
Family
ID=77391258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3168001A Pending CA3168001A1 (en) | 2020-02-21 | 2021-02-21 | Glp-1r and gcgr agonists, formulations, and methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210290732A1 (https=) |
| EP (1) | EP4106796A4 (https=) |
| JP (2) | JP7752619B2 (https=) |
| KR (1) | KR20220143923A (https=) |
| CN (1) | CN115427065A (https=) |
| AU (1) | AU2021224246A1 (https=) |
| BR (1) | BR112022016470A2 (https=) |
| CA (1) | CA3168001A1 (https=) |
| IL (1) | IL295744A (https=) |
| MX (1) | MX2022010320A (https=) |
| WO (1) | WO2021168386A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108892709A (zh) * | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| MX360816B (es) * | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| US20230317230A1 (en) * | 2019-05-02 | 2023-10-05 | Closed Loop Medicine Ltd. | Method for treating obesity |
| CN117202924A (zh) * | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| CN118234742A (zh) * | 2021-12-01 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | Glp-1和gip受体双重激动剂的药物组合物及其用途 |
| JP2025537192A (ja) * | 2022-11-05 | 2025-11-14 | スピットファイア ファーマ エルエルシー | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008513384A (ja) * | 2004-09-17 | 2008-05-01 | ノボ ノルディスク アクティーゼルスカブ | インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物 |
| MX2007005521A (es) * | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| CN108892709A (zh) * | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| MX360816B (es) * | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| ES2906975T3 (es) * | 2012-11-20 | 2022-04-21 | Eumederis Pharmaceuticals Inc | Productos farmacéuticos de péptidos mejorados |
| EP2986313B1 (en) * | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| PT3155017T (pt) * | 2014-05-28 | 2024-05-14 | Mederis Diabetes Llc | Farmacêuticos peptídicos melhorados para resistência à insulina |
| JP2017517549A (ja) * | 2014-06-13 | 2017-06-29 | サノフイ | 活性薬剤成分のナノカプセル製剤 |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| AU2015320545C1 (en) * | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| EP4523705A3 (en) * | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| EP4506017A3 (en) * | 2018-01-03 | 2025-05-14 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
-
2021
- 2021-02-21 CA CA3168001A patent/CA3168001A1/en active Pending
- 2021-02-21 WO PCT/US2021/018947 patent/WO2021168386A1/en not_active Ceased
- 2021-02-21 IL IL295744A patent/IL295744A/en unknown
- 2021-02-21 EP EP21757069.6A patent/EP4106796A4/en active Pending
- 2021-02-21 AU AU2021224246A patent/AU2021224246A1/en active Pending
- 2021-02-21 CN CN202180029769.4A patent/CN115427065A/zh active Pending
- 2021-02-21 MX MX2022010320A patent/MX2022010320A/es unknown
- 2021-02-21 JP JP2022548518A patent/JP7752619B2/ja active Active
- 2021-02-21 US US17/180,827 patent/US20210290732A1/en active Pending
- 2021-02-21 KR KR1020227032683A patent/KR20220143923A/ko active Pending
- 2021-02-21 BR BR112022016470A patent/BR112022016470A2/pt unknown
-
2025
- 2025-01-22 US US19/034,251 patent/US20250262280A1/en active Pending
- 2025-09-29 JP JP2025162266A patent/JP2026021305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021224246A1 (en) | 2022-09-15 |
| US20210290732A1 (en) | 2021-09-23 |
| JP2026021305A (ja) | 2026-02-10 |
| CN115427065A (zh) | 2022-12-02 |
| EP4106796A4 (en) | 2024-04-17 |
| US20250262280A1 (en) | 2025-08-21 |
| EP4106796A1 (en) | 2022-12-28 |
| IL295744A (en) | 2022-10-01 |
| BR112022016470A2 (pt) | 2022-11-22 |
| JP2023514992A (ja) | 2023-04-12 |
| JP7752619B2 (ja) | 2025-10-10 |
| KR20220143923A (ko) | 2022-10-25 |
| MX2022010320A (es) | 2023-01-30 |
| WO2021168386A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12257229B2 (en) | Peptide pharmaceuticals for treatment of NASH and other disorders | |
| US20250262280A1 (en) | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | |
| US20240148879A1 (en) | Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use | |
| US20250134963A1 (en) | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | |
| US20240269238A1 (en) | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | |
| US12171806B2 (en) | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | |
| US20240277815A1 (en) | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | |
| EP4611792A1 (en) | Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist | |
| HK40101792A (zh) | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250214 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250214 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250214 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250730 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250730 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20251016 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251016 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20251016 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251016 Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251016 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251016 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251016 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251016 |